Cancer Blood-Test Startup Guardant Raises Almost $100 Million
- Investors include OrbiMed, Khosla, Sequoia, Formation 8
- Company's `liquid biopsies' replace older invasive procedures
This article is for subscribers only.
Guardant Health Inc. raised almost $100 million in its latest funding round as the startup seeks to expand the use of blood tests to screen for cancer DNA, replacing traditional invasive procedures for tissue samples.
The fundraising was led by health-care investment firm OrbiMed Advisors and included Khosla Ventures, Sequoia Capital and Formation 8, Guardant said Thursday in a statement. The Silicon Valley startup, based in Redwood City, California, is waiting for some final investors before closing the round and can’t yet provide an exact total, Chief Executive Officer Helmy Eltoukhy said. He declined to comment on the startup’s valuation.